ELEISA FLOYD: Open Payments
NPI 1376051235 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,105 in 91 payments from 27 companies in 2025. Trend: 2023 $1,268 · 2024 $1,008 · 2025 $2,105
Food & beverage: $2,062Education: $43
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $245 |
| ABBVIE INC. | 11 | $243 |
| Neurocrine BioSciences, Inc. | 10 | $198 |
| Merck Sharp & Dohme LLC | 8 | $161 |
| Alkermes, Inc. | 8 | $160 |
| Novo Nordisk Inc | 2 | $114 |
| Janssen Pharmaceuticals, Inc | 6 | $109 |
| Pharming Healthcare, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 2 | $86 |
| ViiV Healthcare Company | 4 | $69 |
Products named: INGREZZA, VRAYLAR, PIFELTRO, AIRSUPRA, ARISTADA, Ozempic, RUCONEST, COBENFY.
Industry payments across LA — which companies pay providers there.
